Pasithea Therapeutics to Call Special Meeting of Stockholders

Pasithea Therapeutics to Call Special Meeting of Stockholders ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ Pasithea Therapeutics to Call Special Meeting of Stockholders MIAMI BEACH, Fla., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (CNS) disorders, today announced that Camac Partners, LLC, Camac Capital, LLC, Concord IP2 Ltd., Elderhill Corporation, Leonite Capital LLC, Eric Shahinian, David Delaney, and Avi Geller (collectively, the “Camac Group”) satisfied the necessary requirements to call a Special Meeting of Stockholders (“Special Meeting”). The Company was notified that the Camac Group demonstrated the requisite votes on September 28, 2022, and notes that, contrary to their public statements, the Camac Group’s notifications prior to that date were invalid. Pasithea will call a Special Meeting in accordance with the Company’s bylaws. Additional details about the Special Meeting will be forthcoming. There is no action required by stockholders. The Company stated, “During our first year as a public company, Pasithea has made significant progress towards our mandate to develop novel and groundbreaking drugs, including achieving positive preclinical results for our drug discovery programs, strengthening our team of scientists, expanding our portfolio with complementary CNS therapies with significant potential, and enhancing our recently reelected Board of Directors. We are excited about Pasithea’s future scientific and value creation prospects, and look forward to continued engagement with our stockholders.” McDermott Will & Emery LLP are serving as legal advisor to the Company and Kingsdale Advisors is serving as an advisor in connection with the activities of the Camac Group. About Pasithea Therapeutics Corp. Pasithea Therapeutics Corporation is a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (CNS) disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Pasithea addresses the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings. Forward Looking Statements This press release contains statements that constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the SEC. Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law. Such forward-looking statements are subject to risks (including those set forth in the Company’s Form 10-K for the fiscal year ended December 31, 2021, as amended, filed with the U.S. Securities and Exchange Commission) and uncertainties which could cause actual results to differ from the forward-looking statements. Important Additional Information and Where to Find It This communication may be deemed solicitation material in respect of the Special Meeting. The Company plans to file a proxy statement with the Securities and Exchange Commission, in connection with the solicitation of proxies for the Special Meeting. Stockholders are urged to read such proxy statement (including any amendments or supplements thereto) and any other relevant documents that the Company files with the SEC carefully in their entirety when they become available because they will contain important information. Certain Information Regarding Participants to the Solicitation Pasithea, its directors and certain of its executive officers and employees are deemed to be participants in a solicitation of requests not to vote for the Camac Group’s proposal at the Special Meeting (the “Special Meeting Solicitation”). Information regarding the identity of these potential participants and their direct or indirect interests, by security holdings or otherwise, is set forth in the Consent Revocation Solicitation Statement filed by Pasithea with the Securities and Exchange Commission on July 28, 2022. Pasithea Therapeutics Corp. Company Contact Dr. Tiago Reis Marques Chief Executive Officer E: [tiago@pasithea.com](~/AASl5QA~/RgRlHsWkP0TlaHR0cHM6Ly93d3cuZ2xvYmVuZXdzd2lyZS5jb20vVHJhY2tlcj9kYXRhPUlmY21RQnRoSjRwd0RPcGI0NEROX1RhWWZuZzBzV1NBVkxmMEJLdTJpbXA4M2VmaVp3UjM4Q3BPUGZhcjREWHY1QnEzaTFfTHZNclM3X1J4dlZTMGhNRjJYbmFvNXhNQzhyZFozUGVCY0RnJTNEJl9reD1fLUhTcG8yeTlsRFdKZTVmSzZ4MzZiYUlmdXFyWVNqcm1Jd0lOT2pwT0Y5N3lwNV9vMzd3Tm9JTXpOVDBsMkRYLlRhOXJoTFcDc3BjQgpjM6RAPGNUqRMkUht0cmlzdHJhbWJhbGR3aW44N0BnbWFpbC5jb21YBAAF4bE~) Michael Fein Kingsdale Advisors T: 646-651-1641 E: [mfein@kingsdaleadvisors.com](~/AASl5QA~/RgRlHsWkP0T3aHR0cHM6Ly93d3cuZ2xvYmVuZXdzd2lyZS5jb20vVHJhY2tlcj9kYXRhPWkxeUNKQWRldE5kbkRWbWFwNUVxeHlaYjU2QVluV0VxTkQ0Wl9pWk1DNVpUM1A1MWYxTmd1dDdtOFFYenM2WkV1QjVNZ3NRV2M2NHVDOWpRZnFXQVhiU3V6S1FYMkFicS1CUUtfdjVZYTU3MnhVQllERk9RYUhyU0FSOC1NMEpZJl9reD1fLUhTcG8yeTlsRFdKZTVmSzZ4MzZiYUlmdXFyWVNqcm1Jd0lOT2pwT0Y5N3lwNV9vMzd3Tm9JTXpOVDBsMkRYLlRhOXJoTFcDc3BjQgpjM6RAPGNUqRMkUht0cmlzdHJhbWJhbGR3aW44N0BnbWFpbC5jb21YBAAF4bE~) Pasithea Therapeutics Corp. Media Contact Paul Caminiti/Nicholas Leasure Reevemark T: 212-433-4600 E: [PasitheaTeam@reevemark.com](~/AASl5QA~/RgRlHsWkP0T3aHR0cHM6Ly93d3cuZ2xvYmVuZXdzd2lyZS5jb20vVHJhY2tlcj9kYXRhPXVKNXo2YmJlSFJoNENqV1NRbnlqNDI5QnBLaGxneDJDODVTRHRadktGX1NrZ1lXdzFSaG9WNGEteWlTbDRic0JLVlQwVHhMRXVON0dRSDlGZkVJY1I4SXhmQzJ1Tld5UGN3MmdSaTlpc3EtaElYSTFJa0xlNWdxWGVZUDhMTlM1Jl9reD1fLUhTcG8yeTlsRFdKZTVmSzZ4MzZiYUlmdXFyWVNqcm1Jd0lOT2pwT0Y5N3lwNV9vMzd3Tm9JTXpOVDBsMkRYLlRhOXJoTFcDc3BjQgpjM6RAPGNUqRMkUht0cmlzdHJhbWJhbGR3aW44N0BnbWFpbC5jb21YBAAF4bE~) Pasithea Therapeutics Corp. Investor Relations Lisa M. Wilson In-Site Communications, Inc. T: 212-452-2793 E: [lwilson@insitecony.com](~/AASl5QA~/RgRlHsWkP0TlaHR0cHM6Ly93d3cuZ2xvYmVuZXdzd2lyZS5jb20vVHJhY2tlcj9kYXRhPTRWNVczb0JnbWRBZjQ1N0xTRjNlZVJ6X1p1dE9UcDh3anRWMUdjUV85emRWdEVpYll5QjlOZmlPR3hSeWIxR1VYVzZDMmpqM0pRWmlpbEFNLVJwV1JQdnBxTW9OYkVLcEkzZGI2MEZxQVo4JTNEJl9reD1fLUhTcG8yeTlsRFdKZTVmSzZ4MzZiYUlmdXFyWVNqcm1Jd0lOT2pwT0Y5N3lwNV9vMzd3Tm9JTXpOVDBsMkRYLlRhOXJoTFcDc3BjQgpjM6RAPGNUqRMkUht0cmlzdHJhbWJhbGR3aW44N0BnbWFpbC5jb21YBAAF4bE~) ~/AASl5QA~/RgRlHsWkP0TlaHR0cHM6Ly93d3cuZ2xvYmVuZXdzd2lyZS5jb20vVHJhY2tlcj9kYXRhPVBSam5LeDhsOUhETkx5Mi1vaUowX3FBZXBuNVNNOERKbFZ3Z0VLMEJuY0R1RFI4LTd5bXFVb2pONzd5N2h2aGlxU0tTODF2OXYwY3pfTnpxaW5FWS11dlZGQ3ZrX2NyZzNkSEI4N3JHeU9JJTNEJl9reD1fLUhTcG8yeTlsRFdKZTVmSzZ4MzZiYUlmdXFyWVNqcm1Jd0lOT2pwT0Y5N3lwNV9vMzd3Tm9JTXpOVDBsMkRYLlRhOXJoTFcDc3BjQgpjM6RAPGNUqRMkUht0cmlzdHJhbWJhbGR3aW44N0BnbWFpbC5jb21YBAAF4bE~ This website is wholly owned by scd media llc (d/b/a “smallcapsdaily.com”). Our reports are advertorials and are for general information purposes only. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our services, joining our email list, as well as any social networking platforms we may use. Please note as well: Small Caps Daily and its employees are not Registered Investment Advisors, broker-dealers, or member(s) of any association for other research providers in any jurisdiction whatsoever. release of liability: through use of this website, viewing or using you agree to hold Small Caps Daily, its operators, owners, and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Small Caps Daily encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the company profiled or is available from public sources and Small Caps Daily makes no representations, warranties, or guarantees as to the accuracy or completeness of the disclosure by the profiled company. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Small Caps Daily strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Small Caps Daily’s full disclosure is to be read and fully understood before using Small Caps Daily's website, or joining Small Caps Daily's email or text list. From time to time, Small Caps Daily will disseminate information about a company via website, email, sms, and other points of media. By viewing Small Caps Daily's website and/or reading Small Caps Daily's email or text newsletter you are agreeing to this ----> . All potential percentage gains discussed in any communications are based on calculations from the low to the high of the day. We are engaged in the business of marketing and advertising companies for monetary compensation. In compliance with section 17(b) of the securities act we are disclosing that we have been compensated a fee pursuant to an agreement between scd media llc and sea path advisory. Small Caps Daily was hired for a period beginning january 2022 and ending march 2022 to publicly disseminate information about Pasithea Therapeutics Corp. via website, email, and sms. We were paid five thousand usd via ACH. We are also disclosing that Tradigital Marketing Group has been compensated a fee pursuant to an agreement between Tradigital and Pasithea Therapeutics Corp. Tradigital was hired for a period beginning january 2022 and ending march 2022 to publicly disseminate information about Pasithea Therapeutics Corp., via website, email, and SMS. Tradigital was paid three hundred ninety-four thousand USD via ACH. Subsequently, Tradigital was paid four hundred ninety-nine thousand USD via ACH. Tradigital owns one hundred fifty thousand restricted common shares of Pasithea Therapeutics Corp., which are eligible for sale on 03/18/2022. For the purpose of this disclaimer, we suggest that you assume we will sell all of our shares once the restriction is lifted on 03/18/2022. Readers are advised to review sec periodic reports: forms 10-q, 10k, form 8-k, insider reports, forms 3, 4, 5 schedule 13d. Small Caps Daily is compliant with the can-spam act of 2003. Small Caps Daily does not offer investment advice or analysis, and Small Caps Daily further urges you to consult your own independent tax, business, financial, and investment advisors. investing in micro-cap, small-cap, and growth securities is highly speculative and carries an extremely high degree of risk. it is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled.the private securities litigation reform act of 1995 provides investors a safe harbor in regard to forward-looking statements. any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events, or performance are not statements of historical fact may be forward-looking statements. forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quotes; may, could, or might occur. understand there is no guarantee past performance will be indicative of future results in preparing this publication, Small Caps Daily has relied upon information supplied by its clients, as well as its clients’ publicly available information and press releases which it believes to be reliable; however, such reliability can not be guaranteed. investors should not rely on the information contained on this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. the advertisements in this website are believed to be reliable, however, Small Caps Daily and its owners, affiliates, subsidiaries, officers, directors, representatives, and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Small Caps Daily is not responsible for any claims made by the companies advertised herein, nor is Small Caps Daily responsible for any other promotional firm, its program, or its structure. Small Caps Daily is not affiliated with any exchange, electronic quotation system, the securities exchange commission, or finra. No longer want to receive these emails? [Unsubscribe](~/AASl5QA~/RgRlHsWkP0SxaHR0cHM6Ly9tYW5hZ2Uua21haWwtbGlzdHMuY29tL3N1YnNjcmlwdGlvbnMvdW5zdWJzY3JpYmU_YT1UYTlyaEwmYz0wMUdBUDhESDJQN0VCQ0RNSlJUNEs2MjIwNCZrPTc0MWEzMmNkZDk1MjdhYzUyYWYwOTRmMDQ5N2Y1Nzg3Jmc9U2ZQbXJMJm09MDFHRUhORVg5UVdWNERRWDVKNkdHNDg3M1Emcj1URjJxV0w1VwNzcGNCCmMzpEA8Y1SpEyRSG3RyaXN0cmFtYmFsZHdpbjg3QGdtYWlsLmNvbVgEAAXhsQ~~). Small Caps Daily 1334 Northampton St Easton, PA 18042 ‌